Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
6
×
Tags
biotech
boston blog main
boston top stories
cancer
6
×
eli lilly
6
×
indiana blog main
indiana top stories
6
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
alzheimer's disease
cancer immunotherapy
deals
novartis
pfizer
astrazeneca
biogen
bristol-myers squibb
clinical trials
What
drug
6
×
bio
roundup
companies
alzheimer’s
approval
fda
latest
nash
news
price
prices
week
acquisitions
address
annual
approved
approves
assessed
attention
biggest
biogen’s
biopharmaceutical
biotech
blueprint
build
buy
cancer
carries
ceo
certain
communities
company’s
conference
convo
daniel
debut
designed
different
digital
Language
unset
Current search:
cancer
×
drug
×
photo
×
" indiana top stories "
×
" eli lilly "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More